Dr. Alastair Bell oversees the comprehensive system strategy and operations of BMCHS' entities, including BMC, Boston Accountable Care Organization, Clearway Health, and the WellSense Health Plan.

Prior to joining in 2012, Dr. Bell was a leader in the North American payor and provider practice at McKinsey and Company, advising a range of national and international healthcare organizations and leading large-scale transformation programs. He received his Doctor of Medicine from the University of Oxford, his Master of Arts in physiology from the University of Cambridge, and his Master of Business Administration with distinction from Harvard Business School. Dr. Bell currently serves as co-chair of the board for the Boston Children’s Chorus.

Julie Kim is CEO-elect of Takeda. She was appointed by the Takeda Board of Directors to succeed Christophe Weber as president & CEO of Takeda in June 2026. In this role and as part of her transition to CEO, she is focusing on activities that will help set the direction for the company once she assumes the office. She is also serving as the interim head of the Global Portfolio Division.

Julie joined Takeda in 2019 through the acquisition of Shire and has held several diverse roles with increasing responsibility, including president of the Plasma-Derived Therapies Business Unit and president of the U.S. Business Unit. 

With three decades of experience in health care, Julie’s leadership spans global, regional and country-level roles across a variety of therapeutic areas and markets. Renowned for her collaborative and inclusive approach, she is committed to serving patients and advancing innovation. She holds an MBA from Northwestern University’s Kellogg School of Management and a bachelor’s in economics from Dartmouth College.

Since becoming CEO of Novartis in 2018, Vas has led a strategic and cultural transformation to build a fully focused medicines company—one that delivers high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. He leads a company of more than 78 000 associates that does business in approximately 130 countries and that reached more than 250 million patients with innovative medicines in 2023.

Over the last five years, Vas has sharpened the company’s focus on key therapeutic areas and technology platforms, including siRNA, radioligand, and gene and cell therapies, to deliver new medicines for patients with cardiovascular disease, cancer and rare but debilitating genetic disorders. In parallel, he has led a transformation to make culture a driver of innovation, reputation and performance at Novartis, while advancing a digital revolution to use data science and technology to find new ways to discover and develop medicines and increase efficiency.

Vas has focused his education and career on improving human health and on his personal purpose of inspiring a healthier world. During and after his medical studies, he worked on public health issues such as HIV/AIDS, malaria and tuberculosis in India, Africa and South America. He continues to champion access and global health priorities, including through a commitment by Novartis to expand access to innovative medicines in low- and middle-income countries by at least 200% by 2025.

Since joining Novartis in 2005, Vas has held a range of leadership roles, including Global Head of Development for Novartis Vaccines, and Global Head of Drug Development and Chief Medical Officer. In recognition of his sustained efforts to improve human health, he is an elected member of the National Academy of Medicine in the US, and a member of the board of fellows at Harvard Medical School. Vas previously served as chair of the Pharmaceutical Research and Manufacturers of America (PhRMA), and remains on its board of directors.

Originally from Pittsburgh, Pennsylvania, Vas lives in Basel, Switzerland, with his wife and two sons. A lifelong vegetarian, he is passionate about environmental and wildlife conservation — and is Chair of the African Parks Network in South Africa. He is an avid reader on topics including history, leadership and philosophy.

Patrick Gilligan is an accomplished health care executive with more than 25 years of leadership experience spanning health plans, provider systems, and retail health. As Chief Executive Officer of Point32Health, he leads one of New England’s largest health plans through a transformative era of performance improvement and stakeholder collaboration, with unprecedented opportunities to engage members in their own health.

Patrick brings a unique dual-lens perspective, having held senior executive roles on both the payer and provider sides of health care. Prior to Point32Health, he was a senior advisor with CWH Advisors, where he led strategic turnaround work for major health systems including Baylor Scott & White Health. He previously served as Chief Commercial Officer and Executive Vice President at Blue Cross Blue Shield of Massachusetts (BCBSMA), where he oversaw all market-facing functions and led key initiatives to rebuild market trust, grow membership, and expand digital and value-based care capabilities.

Patrick has also served as President of Indigo Insurance Services and CEO of Zaffre Investments, two subsidiaries of BCBSMA, where he directed strategic investment initiatives and expanded specialty insurance offerings. Previously, Patrick held leadership roles at CVS Health as Senior Vice President of Health System Alliances, where he developed strategic partnerships with more than 60 health systems to advance care delivery via the MinuteClinic platform. At Partners HealthCare (now Mass General Brigham), he helped lead payer contracting and financial strategy across the system.

Patrick, a New England native, holds a Bachelor of Arts in Mathematics from the College of the Holy Cross and is a former Associate of the Society of Actuaries. He currently serves on the Board of United Way of Massachusetts Bay and has held governance roles with Blue Venture Fund, Greater Boston Chamber of Commerce, and Cobalt Benefits Group.